Navigating the Recent Rheumatoid Arthritis Guidelines to Achieve Disease Remission and Reduce Patient Burden

To participate in this activity, please:

In this subway-themed activity, Roy M. Fleischmann, MD, discusses the latest evidence for the management of patients with moderate-to-severe rheumatoid arthritis who do not achieve treatment goals with initial disease-modifying anti-rheumatic drug therapy. A key treatment principle emphasized by Dr. Fleischmann is using a treat-to-target approach guided by validated tools for assessing disease activity and patient-reported outcomes. Among the treatment options, Dr. Fleischmann highlights the pharmacology of the latest approved treatments for rheumatoid arthritis. Using case scenarios, he illustrates how they might be integrated with other therapies.

Course Credit:

1 AMA PRA Category 1 CreditTM


Opens: 2020-10-16
Closes: 2021-10-15

Target Audience:

This activity was developed for a national audience of rheumatologists, primary care physicians, nurse practitioners, physician assistants and other healthcare providers who manage patients with rheumatoid arthritis.

This activity is supported by an independent educational grant from Sanofi Genzyme.

    Presenting Faculty

  • Roy M. Fleischmann, MD

    Clinical Professor of Medicine
    University of Texas Southwestern Medical Center
    Medical Director
    Metroplex Clinical Research Center
    Dallas, Texas